Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calcium Overloading-Induced UBE2O Upregulation Alleviates Neuronal Apoptosis.

Molecular neurobiology·2026
Same author

ZER1 Restrains Pressure Overload-Induced Cardiac Remodeling by Targeting DVL2 for Gly/N-Degron-Dependent Degradation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Duration-dependent effects of sucrose intake on fear extinction via distinct mechanisms in the amygdala and hippocampus.

Brain research·2026
Same author

Synthesis of aza-β-lactams <i>via</i> B(C<sub>6</sub>F<sub>5</sub>)<sub>3</sub>-catalyzed Wolff rearrangement/[2 + 2] cascade cyclization of α-diazoketones with diazenes.

Organic & biomolecular chemistry·2026
Same author

Deep Learning for Classifying and Cognitive Profiling of Subcortical Vascular Cognitive Impairment.

Cyborg and bionic systems (Washington, D.C.)·2026
Same author

Multimodal clocks of human aging.

Cell·2026

Related Experiment Video

Updated: Sep 12, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.0K

Improving Alzheimer's disease immunotherapy.

Mengen Xing1, Weihong Song1,2

  • 1Center for Geriatric Medicine, International Center for Alzheimer's Research, Prevention and Treatment, The First Affiliated Hospital and Oujiang Laboratory; Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, Zhejiang, China.

Science (New York, N.Y.)
|August 7, 2025
PubMed
Summary
This summary is machine-generated.

A novel modified antibody targeting amyloid-beta (Aβ) peptides demonstrated improved safety and effectiveness in preclinical Alzheimer's disease research. This antibody shows promise for future therapeutic development against Aβ pathology.

More Related Videos

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.1K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.4K

Related Experiment Videos

Last Updated: Sep 12, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.0K
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.1K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.4K

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Amyloid-beta (Aβ) plaques are a hallmark of Alzheimer's disease (AD).
  • Current Aβ-targeting therapies can cause adverse events like amyloid-related imaging abnormalities (ARIA).

Purpose of the Study:

  • To develop and evaluate a modified antibody for enhanced Aβ targeting with reduced side effects.
  • To assess the efficacy and safety of this modified antibody in a mouse model of AD.

Main Methods:

  • Engineering an antibody with specific modifications to alter its interaction with Aβ.
  • Administering the modified antibody to transgenic mice exhibiting Aβ pathology.
  • Assessing Aβ plaque load, cognitive function, and incidence of adverse events.

Main Results:

  • The modified antibody significantly reduced Aβ plaque burden compared to control.
  • A notable decrease in adverse events, such as ARIA, was observed.
  • Improved cognitive performance was correlated with reduced Aβ pathology.

Conclusions:

  • Antibody modification can enhance therapeutic efficacy against Aβ in a mouse model.
  • This approach shows potential for improving the safety profile of Aβ-targeting AD therapies.